mTOR/α-ketoglutarate-mediated signaling pathways in the context of brain neurodegeneration and neuroprotection
BBA Advances, ISSN: 2667-1603, Vol: 2, Page: 100066
2022
- 8Citations
- 20Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes8
- Captures20
- Readers20
- 20
- Mentions2
- News Mentions2
- News2
Most Recent News
New Findings from National Academy of Sciences of Ukraine Describe Advances in Neurodegeneration (mTOR/a-ketoglutarate-mediated signaling pathways in the context of brain neurodegeneration and neuroprotection)
2022 DEC 06 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- New study results on neurodegeneration have been published. According
Article Description
Cerebral disorders are largely associated with impaired cellular metabolism, despite the regulatory mechanisms designed to ensure cell viability and adequate brain function. Mechanistic target of rapamycin (mTOR) signaling is one of the most crucial factors in the regulation of energy homeostasis and its imbalance is linked with a variety of neurodegenerative diseases. Recent advances in the metabolic pathways’ modulation indicate the role of α-ketoglutarate (AKG) as a major signaling hub, additionally highlighting its anti-aging and neuroprotective properties, but the mechanisms of its action are not entirely clear. In this review, we analyzed the physiological and pathophysiological aspects of mTOR in the brain. We also discussed AKG’s multifunctional properties, as well as mTOR/AKG-mediated functional communications in cellular metabolism. Thus, this article provides a broad overview of the mTOR/AKG-mediated signaling pathways, in the context of neurodegeneration and endogenous neuroprotection, with the aim to find novel therapeutic strategies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2667160322000266; http://dx.doi.org/10.1016/j.bbadva.2022.100066; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142330751&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37082603; https://linkinghub.elsevier.com/retrieve/pii/S2667160322000266; https://dx.doi.org/10.1016/j.bbadva.2022.100066
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know